Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia.

Jason ChenJustine Abella RossBernard TegtmeierDongyun YangJames I ItoJohn A ZaiaJana K DickterRyotaro NakamuraSally MokhtariJane KriengkauykiatMonzr M Al MalkiSanjeet S Dadwal

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2019)

Preemptive anti-CMV therapy is associated with major healthcare resource costs, which were greater in patients who required FOS than those who were treated with GCV.

Keyphrases

healthcare
bone marrow
stem cell transplantation
cell therapy
single cell
epstein barr virus
hematopoietic stem cell
stem cells
low dose
high dose
health information